Clinical trials: Neonatal Respiratory Distress
Respiratory Distress Syndrome in Premature Infant, Bronchopulmonary Dysplasia
Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome
Bronchopulmonary Dysplasia (BPD) is a multi-factorial disease process that is the end result of an immature, surfactant deficient lung that has been exposed to hyperoxia, mechanical ventilation and infection.
- Trial name
- NCT01941745
- Testing
- Half normal saline, Low Dose rhCC10, High dose rhCC10
- Where
- 3 sites in United States
- Volunteers
- 88 people
- Sponsor
- Tufts Medical Center
Respiratory Distress Syndrome
Early CPAP And Large Volume Minimally Invasive Surfactant (ECALMIST) in Preterm Infants With RDS
Modification of Minimally Invasive Surfactant Therapy (MIST) to a new technique called ECALMIST (Early CPAP And Large volume Minimal Invasive Surfactant).
- Trial name
- ECALMIST (NCT01553292)
- Testing
- ECALMIST
- Where
- 3 sites in Canada
- Volunteers
- 21 people
- Sponsor
- University of Manitoba
Intubated Infants Were Intend to Extubation Using Noninvasive Ventilation Strategies
A Trial Comparing Noninvasive Ventilation Strategies in Preterm Infants Following Extubation
Respiratory distress syndrome (RDS) is the main cause of respiratory failure in preterm neonates, its incidence varying from 80% to 25% depending on gestational age.When optimal prenatal care is provided, the best approach to…
- Trial name
- NCT03181958
- Testing
- NHFOV, NCPAP, NIPPV
- Where
- China
- Volunteers
- 1,493 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Lung Injury, Acute (ALI), Respiratory Distress Syndrome, Acute (ARDS)
Comparative Evaluation of Albumin and Starch Effects in Acute Lung Injury (ALI)
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are similar conditions in which the lungs are critically injured by another inflammatory process in the body.
- Trial name
- CEASE (NCT00796419)
- Testing
- 5% human albumin, 6% hetastarch
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Emory University
Corona Virus Infection, Acute Respiratory Distress Syndrome
Losartan for Patients With COVID-19 Not Requiring Hospitalization
This is a multi-center, double-blinded study of COVID-19 infected patients randomized 1:1 to daily losartan or placebo for 10 days or treatment failure (hospital admission).
- Conditions
- Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection
- Trial name
- NCT04311177
- Testing
- Losartan
- Where
- 4 sites in United States
- Volunteers
- 117 people
- Sponsor
- University of Minnesota
Acute Respiratory Distress Syndrome, SARS-CoV-2
Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19
Evaluation of the safety, tolerability, and pharmacokinetics of PLN-74809 in participants with acute respiratory distress syndrome (ARDS) associated with at least severe COVID-19
- Trial name
- NCT04565249
- Testing
- PLN-74809
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Pliant Therapeutics, Inc.
Apnea of Prematurity, Respiratory Distress Syndrome
A Comparison of Methods of Discontinuing Nasal CPAP in Premature Infants <30 Weeks Gestation
The purpose of this study is to determine if among infants <30 weeks gestational age on nasal continuous positive airway pressure (NCPAP), whether discontinuing CPAP after gradual reduction in continuous positive airway pressure…
- Trial name
- NCT03292562
- Testing
- Discontinue NCPAP after weaning pressures, Discontinue NCPAP without weaning pressures
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- The University of Texas Health Science Center, Houston
Coronavirus Infections, Pneumonia, Viral
Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19
The scientific community is in search for novel therapies that can help to face the ongoing epidemics of novel Coronavirus (SARS-Cov-2) originated in China in December 2019.
- Conditions
- Coronavirus Infections, Pneumonia, Viral, Acute Respiratory Distress Syndrome
- Trial name
- NoCovid (NCT04305457)
- Testing
- Nitric Oxide
- Where
- 2 sites in United States
- Volunteers
- 62 people
- Sponsor
- Massachusetts General Hospital
Respiratory Distress Syndrome, Newborn
Comparison of CPAP Machines With Reusable vs Disposable Circuits
The study aims to assess the basic functionality of a newly designed CPAP machine with reusable circuits to existing machines with disposable circuits, for treatment of newborn infants diagnosed with respiratory distress…
- Trial name
- NCT03121612
- Testing
- CPAP
- Where
- India
- Volunteers
- 51 people
- Sponsor
- Medical Technology Transfer and Services Hong Kong Ltd
ARDS, Critical Illness
Implementation of Nudges to Promote Utilization of Low Tidal Volume Ventilation (INPUT) Study
This study is a large pragmatic stepped-wedge trial of electronic health record (EHR)-based implementation strategies informed by behavioral economic principles to increase lung-protective ventilation (LPV) utilization among all…
- Conditions
- ARDS, Critical Illness, Acute Respiratory Distress Syndrome, Acute Respiratory Failure
- Trial name
- INPUT (NCT04663802)
- Testing
- Default order set, Physician-targeted accountable justification, Respiratory therapist (RT)-targeted accountable justification
- Where
- 5 sites in United States
- Volunteers
- 7,342 people
- Sponsor
- University of Pennsylvania
Acute Respiratory Distress Syndrome, Shock
Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure
The objective of our study is to evaluate the efficacy of helmet ventilation as compared with Face mask in patients with respiratory failure.
- Conditions
- Acute Respiratory Distress Syndrome, Shock, Ventilatory Failure, Cardiogenic Pulmonary Edema
- Trial name
- NCT01680783
- Testing
- Non invasive ventilation using a helmet hyperbaric device, Noninvasive ventilation via facemask
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- University of Chicago
Respiratory Distress Syndrome, Newborn
Surfactant Via Endotracheal Tube vs. Laryngeal Mask Airway (LMA) in Preterm Neonates With Respiratory Distress Syndrome
In this study, newborn babies with respiratory distress syndrome (RDS), receiving oxygen via nasal continuous airway pressure (CPAP) modalities, and needing surfactant treatment will be randomized to standard delivery of…
- Trial name
- NCT02164734
- Testing
- Endotracheal intubation, Laryngeal mask airway, remifentanil
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Albany Medical College
to Test the Hypothesis That NHFOV is More Effective Than nCPAP in the Treatment of Respiratory Distress Syndrome (RDS) in Verypreterm Neonates
NHFOV as Primary Support in Very Preterm Infants With RDS
This will be a prospective, multi-center, two-arms,parallel, randomized, controlled trial with a superiority design,conducted in China.
- Trial name
- NCT05141435
- Testing
- infants receive primary non-invasive respiratory support by mean of nCPAP, infants receive primary non-invasive respiratory support by mean of NHFOV
- Where
- 3 sites in China
- Volunteers
- 360 people
- Sponsor
- Jiulongpo No.1 People's Hospital
Acute Respiratory Distress Syndrome, Cytokine Release Syndrome
Efficacy and Safety of Itolizumab in COVID-19 Complications
Randomized, Parallel Group, Active Controlled Trial
- Conditions
- Acute Respiratory Distress Syndrome, Cytokine Release Syndrome, Covid19
- Trial name
- NCT04475588
- Testing
- Itolizumab IV infusion, Best supportive care (BSC)
- Where
- 4 sites in India
- Volunteers
- 32 people
- Sponsor
- Biocon Limited
COVID-19
Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)
Phase IV study to evaluate the effectiveness of additional inhaled sargramostim (GM-CSF) versus standard of care on blood oxygenation in patients with COVID-19 coronavirus infection and acute hypoxic respiratory failure.
- Trial name
- SARPAC (NCT04326920)
- Testing
- Sargramostim, Control
- Where
- 4 sites in Belgium
- Volunteers
- 87 people
- Sponsor
- University Hospital, Ghent
Acute Respiratory Distress Syndrome, Covid19
Study of Descartes-30 in Acute Respiratory Distress Syndrome
Emergency study to test the safety of Descartes-30 cells in patients with moderate-to-severe acute respiratory distress syndrome (ARDS) AND COVID-19
- Trial name
- NCT04524962
- Testing
- Descartes 30
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Cartesian Therapeutics
COVID, Corona Virus Infection
hCT-MSCs for COVID19 ARDS
This is a 50 patient, Phase 1/2a multi-center pilot study to test the safety and to describe the preliminary efficacy of intravenous administration of allogenic human cord tissue mesenchymal stromal cells (hCT-MSC) as an…
- Conditions
- COVID, Corona Virus Infection, COVID19
- Trial name
- NCT04399889
- Testing
- Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University.
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Joanne Kurtzberg, MD
Respiratory Distress Syndrome in Premature Infant
A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact
The purpose of this two-part Phase 2 study is to assess the safety, tolerability and efficacy of aerosolized SF-RI 1 (AeroFact) when delivered via nCPAP at two different doses.
- Trial name
- NCT03969992
- Testing
- AeroFact, nCPAP
- Where
- 41 sites in United States, Canada
- Volunteers
- 261 people
- Sponsor
- Aerogen Pharma Limited
Bronchopulmonary Dysplasia
Trial II of Lung Protection With Azithromycin in the Preterm Infant
The hypothesis of this study is that administration of azithromycin to ventilated premature infants will decrease the incidence and severity of BPD.
- Trial name
- NCT00319956
- Testing
- Azithromycin
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- Hubert Ballard
COVID-19, Acute Respiratory Distress Syndrome (ARDS)
Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019
This was a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter, dose escalation and proof-of-concept study to evaluate the safety and efficacy of razuprotafib, administered 3 times daily (TID)…
- Trial name
- RESCUE (NCT04511650)
- Testing
- Razuprotafib Subcutaneous Solution
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.